Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas

The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 7 to 59 years with autoimmune rheumatic diseases (ARDs) who are clinically stable and under low-grade or no immunosuppression, as well as in healthy volunteers matched by sex and age.
The main questions it aims to answer are:
Does the vaccine induce adequate seroconversion in patients with ARDs compared to healthy controls? What is the frequency and intensity of common adverse events after vaccination in ARDs patients? Researchers will compare patients with ARDs to healthy controls to evaluate if the vaccine elicits similar immune responses and safety profiles.
All participants will:
* receive a single 0.5 mL dose of the Butantan-DV vaccine via subcutaneous injection;
* undergo blood sample collection before and after vaccination (baseline, Day 42, and Day 400) to assess antibody and cellular responses;
* attend follow-up visits on Days 7, 14, and 42 for safety monitoring and laboratory tests;
* report any symptoms or adverse events using a standardized diary for 42 days;
* be followed for up to one year for long-term safety and immunogenicity assessments.
Researcher will also perform subgroups analysis in:
A viremia subgroup (50 patients and 50 healthy controls) will provide additional samples on Days 1, 7, 14, 28, 42, and-if viremia is detected-Day 68, to evaluate post-vaccination viremia and its duration.
An immunogenicity subgroup (
20% of participants) will undergo cellular immune response testing via flow cytometry to evaluate T-cell responses.

开始日期2026-01-01

申办/合作机构

University of Sao Paulo General Hospital

[+1]

NCT06891950

/ Not yet recruiting临床3期IIT

Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years

This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination.

开始日期2026-01-01

申办/合作机构

Instituto Butantan

[+1]

NCT06805487

/ Recruiting临床1期IIT

A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Historical Controls Against Infection With ZIKV-SJRP Challenge

Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms. Preventing ZIKV is important because if a pregnant person is infected with ZIKV, it can cause birth defects in their unborn child.
The goals of this study are to find out if people who have already been infected with one type of ZIKV can get infected with ZIKV a second time, and to test the ability of the TV003 dengue vaccine to prevent people from getting infected with the ZIKV-SJRP challenge virus.

开始日期2024-09-24

申办/合作机构

National Institute of Allergy & Infectious Diseases

[+1]

100 项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的临床结果

登录后查看更多信息

100 项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的转化医学

登录后查看更多信息

100 项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的专利（医药）

登录后查看更多信息

项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的文献（医药）

2025-11-27·NEW ENGLAND JOURNAL OF MEDICINE

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model

Article

作者: Vandendijck, Yannick ; Van Wesenbeeck, Liesbeth ; Voge, Natalia V. ; Carmolli, Marya ; Amaro-Carambot, Emérito ; De Marez, Tine ; Buelens, Annemie ; Herrera-Taracena, Guillermo ; Mayfield, Jeffrey ; Lenz, Oliver ; Fetter, Isabel ; Sabundayo, Beulah P. ; Durbin, Anna P. ; Fang, Xi ; Van Loock, Marnix ; Ebone, Laura ; Van Eygen, Veerle ; De Meyer, Sandra ; He, Huili ; Lutton, Patricia ; Kakuda, Thomas N. ; Goeyvaerts, Nele ; Rasschaert, Freya ; De Clerck, Kim ; Akli, Ruxandra Draghia ; Pierce, Kristen K. ; Whitehead, Stephen S.

BACKGROUND:

Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available.

METHODS:

In a phase 2a, double-blind, randomized trial, we assigned healthy adults to receive oral mosnodenvir once daily as a low dose (40-mg loading dose followed by 10-mg maintenance dose), medium dose (200 mg followed by 50 mg), or high dose (600 mg followed by 200 mg) or matched placebo. Loading doses were given for 5 days and maintenance doses for 21 days. In a controlled human infection model, participants received subcutaneous inoculation of an underattenuated dengue virus serotype 3 (DENV-3) strain (rDEN3Δ30) on the day of the first maintenance dose (day 1). The primary efficacy end point was the DENV-3 RNA load, assessed as the log₁₀ area under the concentration-time curve from day 1 (immediately before inoculation) through day 29 (AUC_D1-29). The high-dose and placebo groups were compared in the primary end-point analysis. Safety, pharmacokinetic features, and virologic and serologic features were evaluated through day 85.

RESULTS:

The percentage of participants without signs of DENV-3 infection was 0% (0 of 6 participants) with the low dose of mosnodenvir, 17% (1 of 6) with the medium dose, and 60% (6 of 10) with the high dose, as compared with 0% (0 of 7) with placebo. High-dose mosnodenvir led to a significantly lower DENV-3 RNA load, assessed as the log₁₀ AUC_D1-29, than placebo (two-sided P<0.001 by tobit analysis of variance). In this small trial, mosnodenvir did not result in any serious adverse events. Plasma concentrations of mosnodenvir increased from day -5 to day 1 and were maintained through day 21. Among participants with available NS4B sequencing data, emerging amino acid variations in the NS4B region of the rDEN3Δ30 genome were detected in 14 of 14 mosnodenvir recipients and none of 7 placebo recipients.

CONCLUSIONS:

In a controlled human infection model, a high daily dose of oral mosnodenvir led to a significantly lower DENV-3 RNA load than placebo. Mosnodenvir did not result in any serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and Johnson & Johnson; ClinicalTrials.gov number, NCT05048875.).

2025-11-01·VACCINE

Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine

Article

作者: Dos Santos Silva, Gabriel Ferreira ; Silveira, Daniela Haydee Ramos ; Boulos, Fernanda Castro ; da Silva Braga, Regiane ; Infante, Vanessa ; Ramos, Fabiano ; Oliveira, Danise Senna ; Patiño, Elizabeth Gonzalez ; de Camargo Vieira Tenorio, Juliana ; Peixoto de Miranda, Érique José Farias ; de Mesquita Pacheco, Pedro Henrique Theotonio ; de Sousa Moreira, José Alfredo ; Kallás, Esper Georges ; de Oliveira Alves, Lucas Bassolli

METHODS:

We included 700 participants allocated in a ratio 2:2:2:1 in parallel arms to receive any of three lots of simplified Butantan-DV or placebo, aged 18 to 59 years, without previous exposure to dengue in two study sites from a non-endemic area in Southern of Brazil. The consistency of three lots of the Butantan-DV were evaluated by analyzing the serum neutralizing antibody titers against four dengue virus serotypes by virus reduction neutralization test (VRNT₆₀), on the Day 28 post-vaccination. Criterion for lot-to-lot consistency was two-sided 95 % confidence interval (95 % CI) of geometric mean titers (GMT) ratio within the margins of equivalence of >1/2 and < 2.0 for 12 possible pairwise comparison for the three lots and four serotypes in the Per-Protocol Set. Adverse events were analysed according to the frequency and Miettinen & Nurminen method to build 95 % CI for the difference in the binomial proportions of each lot with the placebo group. This trial is registered with ClinicalTrials.gov, NCT02406729.

FINDINGS:

Between November 4th, 2022 and January 16th, 2023, 700 participants were randomized and vaccinated, while 607 (86.7 %) were included in the Per-Protocol Set. From the 12 possible pairwise comparison between three lots and four serotypes of DENV, 10 met the endpoint of equivalence of lots and 2 failed marginally. The overall frequency of vaccine-related adverse events was 90.8 % (544/599) in Butantan-DV group and 76 % (76/100) in placebo group.

INTERPRETATION:

Three lots of simplified formulation were safe and achieved the endpoint of equivalence of lots.

FUNDING:

Intramural Research Program US NIH National Institute of Allergy and Infectious Diseases, Brazilian National Bank for Economic and Social Development, and Fundação Butantan.

2025-09-01·Pediatric Investigation

Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection

Review

作者: Mishra, Hridesh ; Kain, Kevin C. ; Kim, Bridget ; Wang, Ran

ABSTRACT:

Dengue fever remains a significant global health threat, placing nearly half of the world's population at risk. Despite decades of research, developing an effective dengue vaccine continues to face multiple challenges, including antibody‐dependent enhancement (ADE), serotype‐specific efficacy, and logistical barriers to vaccine delivery. This review provides a comprehensive analysis of the historical and current landscape of dengue vaccine development, focusing on CYD‐TDV, TAK‐003, and Butantan‐DV. It examines their efficacy, safety profiles, and limitations, particularly in achieving balanced quadrivalent protection. Additionally, this review highlights key areas for future research, including the impact of ADE, advancements in vaccine platforms, the need for region‐specific vaccine formulations, and the integration of vaccination into broader dengue prevention strategies. Ultimately, sustained investment and global collaboration are crucial for achieving the goal of a dengue‐free world.

项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的新闻（医药）

2025-07-13

·ETPharma

Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

New Delhi: Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec. The trial is co-led by ICMR-National Institute of Translational Virology and AIDS research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, Pune. Currently, there is no antiviral treatment or licensed vaccine against dengue in India. The results of the Phase-1/2 trial has shown no safety concerns for the one-shot vaccine, NIE Director Dr Manoj Murhekar said. "The participants enrolled in the Phase- III trial will be followed up for two-years. This trial will evaluate the efficacy of this tetravalent dengue vaccine," Dr Murhekar said. The multi-centre, double-blind, randomised, placebo-controlled phase-III trial was launched in August last year to evaluate the jab's efficacy, safety and, long-term immunogenicity. The first participant in this trial was vaccinated at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak last year. The development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes. The dengue virus has four serotypes, 1-4, with low cross-protection against each other, meaning individuals can experience repeated infections, Dr Murhekar said. In India, all four serotypes of dengue virus are known to circulate or co-circulate in many regions. The Union Health Ministry in a statement earlier had said that the tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), USA, has shown promising results in clinical trials in Brazil. Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of development. The company has worked extensively on these strains to develop a full-fledged vaccine formulation and holds a process patent for this work. Dengue is a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease. The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organisation (WHO). In India, approximately 75-80 per cent of infections are asymptomatic, yet these individuals can still transmit the infection through the bite of Aedes mosquitoes. Among the 20-25 per cent of cases where symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. In adults, the disease can escalate into severe conditions like dengue hemorrhagic fever and dengue shock syndrome. According to the government data, around 12,043 dengue cases were reported till March this year. In 2024, 2.3 lakh cases and 297 deaths had been recorded.

临床3期疫苗

2025-07-13

·ETPharma

Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

临床3期疫苗

2025-05-09

·药时空

突破在即！全球登革热疫苗研发最新进展盘点

登革热是全球影响范围最广的节肢动物媒介疾病，主要通过埃及伊蚊或白纹伊蚊传播，全球有近一半的人口面临感染的风险。目前，还没有通用的抗登革病毒药物。登革热的流行病学特征复杂，临床表现多样，从无症状感染到危及生命的登革出血热，任何一种DENV血清型（DENV-1、DENV-2、DENV-3、DENV-4）都可能导致不同程度的疾病。感染一种血清型可对相同血清型产生长期免疫力，对其他血清型仅有短暂免疫力，连续感染不同血清型会使重症登革热的风险增加。登革热病例通常无症状或导致轻度发热性疾病。然而，有些病例会发展为重症登革热，可能会出现休克、严重出血或严重器官损伤。这一阶段通常在退烧后开始，之前有一些警告信号，如剧烈腹痛、持续呕吐、牙龈出血、积液、嗜睡或烦躁以及肝脏肿大[1]。据估计，全球每年有超过1亿至4亿例登革热病例，38亿人生活在登革热流行国家，其中大部分位于非洲、美洲和亚洲。2023年报告的登革热病例数最多，世卫组织美洲区域报告了450万例病例和2300例死亡。由于气候变化和城市化，登革热病例可能还会上升并在地理上出现扩大[2]。我国2019—2023年共报告病例43095例，平均报告发病率为0.61/10万，年报告发病率波动显著（AAPC=-3.16%，95% CI：-54.16%~91.47%），主要集中在2019年和2023年，约占近5年总报告病例数的96.83%。各年龄组人群均可发病，30~<40岁年龄组病例占22.6%。全年均有病例发生，6月份开始快速上升，高峰期集中在8—10月份，为34 780例（RR=12.44，LLR=29 262.52，P<0.05）。疫情特征以输入引发本地传播为主，输入病例主要来源于东南亚地区（占86.56%），其中柬埔寨3284例（占46.11%）、缅甸1851例（占25.99%）为病例主要来源国家。不同年份有显著不同，西南地区、华南地区、华东地区发生本地传播疫情风险高，高发地区主要分布在云南和广东[3]。近几十年来，持续的登革热疫情对维护全球公共卫生安全带来了艰巨的挑战，公众迫切需要一种安全有效的登革热疫苗。对于DENV，有效的疫苗必须对4种DENV血清型都产生免疫保护，又要尽可能避免异源血清型继发感染导致ADE效应。目前，进入临床试验阶段的登革热疫苗主要有减毒活疫苗、灭活病毒疫苗、DNA疫苗、重组亚单位疫苗等。详细情况见下表：赛诺菲巴斯德公司研发的四价减毒活疫苗CYD-TDV是首个上市的登革热疫苗，该疫苗以黄热减毒活疫苗（YFV17D）为骨架，用DENV的前体膜蛋白（prM）和包膜蛋白（E）基因取代YFV 17D相应的结构蛋白基因构建而成[4]。TAK-003是由武田制药开发的一种四价登革热减毒活疫苗，最近已获准在欧盟和印度尼西亚用于6~45岁人群预防接种，且无论其血清阳性或阴性都可接种[5]-[6]。目前，TAK-003正在亚洲、拉丁美洲及其他登革热流行国家接受监管审查[7]。武田制药正在开展一项新的临床试验（NCT03999996），以评估第1次接种15个月和24个月后加强接种的效用。结果表明，TAK-003中来自DENV-2骨架的NS被证明可以引发NS特异性T细胞免疫，所以该疫苗对DENV-2（病毒骨架的起源株）的保护效果最高，这表明未来DENV疫苗研发要同时考虑特异性抗体和T细胞表位产生的免疫影响[8]。TV003/TV005是由美国国家过敏与传染病研究所（NIAID）研制的一种处于临床试验阶段的减毒活疫苗。其研发策略主要分为两种：第一种是在3′非翻译区引入30个核苷酸缺失来设计疫苗（rDEN1Δ30、rDEN3Δ30、rDEN4Δ30）[9]；第二种是用DENV-2的prM和E蛋白替代rDEN4Δ30中的prM和E蛋白[10]。TV003 （103 PFU）和TV005（104 PFU的主要差异在于rDEN2/4Δ30组分用量不同。当不同血清型DENV继发感染宿主时，体内预存的DENV抗体会促进第2种DENV进入单核细胞和巨噬细胞。DENV首先与抗体的Fc片段结合，然后在宿主细胞FcγRs（特别是FcγR Ⅱa和FcγR Ⅲa）的介导下进行吸附和侵袭，并抑制Ⅰ型干扰素的产生，从而增强宿主细胞内病毒的复制[11]。交叉免疫应答抗体可以介导同属病毒的ADE效应。几乎所有抗DENV抗体都可以诱导寨卡病毒（ZIKV）感染的ADE效应[12]。交叉免疫应答的非中和抗体识别两种主要的抗原表位，分别是prM蛋白表位和E蛋白上的融合环表位（FLE）。Dai等[13]通过改变FLE构象但保留其中和表位，重新设计了ZIKV亚单位疫苗免疫原。研究发现，免疫诱导的抗体不会与DENV发生交叉反应，这是消除ZIKV感染导致ADE效应的重大突破。与基于野生型毒株的疫苗相比，该疫苗产生的抗体反应具有更好的免疫优势。野生型毒株疫苗引发的抗体反应主要集中在特定的抗体基因上，而此抗体反应更为多样和分散。这意味着此二聚体疫苗能够改变对ZIKV的免疫优势，在免疫应答中减少了与ADE效应相关的抗体反应。晶体结构表明，免疫原二聚体的E蛋白片段在形成过程中被改变，抑制了ADE效应，为避免产生ADE效应的DENV疫苗研发提供了一种思路[14]。参考文献：[1]世界卫生组织.登革热-全球形势[EB/OL].(2023-12-21) [2025-04-08].https://www.who.int/zh/emergencies/disease-outbreak-news/item/2023-DON498.[2] 世界卫生组织.世卫组织预认证新型登革热疫苗[EB/OL].(2024-05-15) [2025-04-08].https://www.who.int/zh/news/item/15-05-2024-who-prequalifies-new-dengue-vaccine.[3] 李卓威, 黄晓霞, 田婷婷, 等. 我国2019—2023年登革热报告病例流行病学特征. 中国热带医学. 2024, 24(8): 925-930 https://doi.org/10.13604/j.cnki.46-1064/r.2024.08.07.[4] Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine[J]. Hum Vaccin, 2010, 6(9).[5]Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union [EB/OL]. (2022-08-22) [2025-04-15]. https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union/.[6]Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union [EB/OL]. (2022-12-08) [2025-04-15]. https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union/.[7]Takeda comienza con las presentaciones regulatorias para la vacuna candidata contra el dengue en la UE y los países endémicos[EB/OL]. (2021-04-01) [2025-04-15]. https://www.takeda.com/es-ar/prensa/2021/takeda-comienza-con-las-presentaciones-regulatorias-para-la-vacuna-candidata-contra-el-dengue-en-la-ue-y-los-paises-endemicos/.[8] Tricou V, Gottardo R, Egan MA, et al. Characterization of the cell-mediated immune response to Takeda′s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting[J]. Vaccine, 2022, 40 (8): 1143-1151.[9] Durbin AP, Kirkpatrick BD, Pierce KK, et al. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine[J]. Vaccine, 2011, 29(42): 7242-7250.[10] Whitehead SS, Hanley KA, Blaney JE Jr, et al. Substitution of the stru识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗临床研究

100 项与 Tetravalent dengue virus vaccine(Instituto Butantan) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
登革热	申请上市	-	Instituto Butantan	-
寨卡病毒感染	临床1期	美国	National Institute of Allergy & Infectious Diseases	2024-09-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05710224 (V181-002, CTgov)	临床2期	登革热	1,364	V181	餘繭憲鑰窪醖淵簾鹹鹹(築淵鹽觸夢膚衊餘獵願) = 鬱鹹膚壓顧膚齋衊範憲淵鏇窪夢範窪鹽壓觸膚 (構觸糧選鑰構廠襯遞餘, 簾齋糧艱網鑰顧鏇築蓋 ~ 醖膚範獵夢餘鹽艱繭齋) 更多	-	2025-11-18
NCT02678455 (TV005, CTgov)	临床2期	登革热	192	TV005 vaccine (TV005 Vaccine)	遞鏇鹹願鹽選製築壓鹹 = 顧觸窪蓋獵積選繭鏇艱鹽壓遞鹽餘觸選夢艱廠 (積製獵範壓鹹窪襯獵願, 鏇製鏇襯網廠簾繭衊鏇 ~ 憲齋網積網鬱網築窪構) 更多	-	2025-01-17
				Placebo (Placebo)	遞鏇鹹願鹽選製築壓鹹 = 襯積遞廠餘鹹顧構鹽選鹽壓遞鹽餘觸選夢艱廠 (積製獵範壓鹹窪襯獵願, 積鬱淵鏇糧壓願蓋淵積 ~ 夢鏇願膚構繭蓋膚鏇鹽) 更多
NCT02678455 (Pubmed \| Lancet Infect Dis) 人工标引	临床2期	登革热	192	TV005 vaccine	廠襯繭壓鹹製窪鬱鬱窪(簾鹽襯餘遞遞齋鑰獵餘) = 網窪構選餘壓憲蓋網鑰鹽網糧憲鏇夢繭鑰艱顧 (鹽衊蓋艱顧鬱淵網艱鹹 ) 更多	积极	2024-02-01
				Placebo	鹽糧壓糧糧獵醖繭遞範(築顧襯築齋鑰廠構衊範) = 鬱醖獵鹽製遞鹽衊蓋醖繭鏇鏇夢淵繭鏇淵蓋鬱 (築築築顧鑰蓋鹹顧鬱顧, 2.4)
NCT02406729 (DEN-03-IB, Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床3期	登革热	16,235	Dengue 1,2,3,4 (attenuated) vaccinetan-Dengue Vaccine (Butantan-DV)	選窪廠遞簾願鏇鏇選範(遞積廠窪網壓願廠範築) = 淵餘醖醖獵範獵鹽醖獵艱獵鹽鏇願選網遞選範 (糧積鬱艱襯範顧衊鏇鑰, 70.0 ~ 86.3) 更多	积极	2024-02-01
				placebo	積夢膚壓糧構遞鬱壓構(鑰衊窪夢遞願獵廠糧餘) = 壓遞蓋遞繭獵憲憲網製範憲餘鬱蓋淵製鹽顧範 (顧願鹽餘蓋範顧壓膚餘 )
NCT01506570 (Pubmed \| PLoS Negl Trop Dis)	临床1期	黄病毒感染	58	TV003 vaccine	衊獵選築遞襯觸餘鹽製(遞齋夢獵遞築繭襯構齋) = few adverse events other than rash, which was predominately mild 簾鹽鹽遞襯觸積鹹蓋選 (遞壓獵鬱構窪蓋壓齋壓 )	-	2017-05-01